NGGT Inc.

From the team at NGGT to all of you – Happy Holidays!

In case you haven’t yet had the chance to visit us on the web, make sure to go to https://nggtbio.com/ to learn more about NGGT, find the latest media coverage and news, and explore our innovative #genetherapy technology, product pipeline and advanced manufacturing capabilities.

Our Chief Executive Officer Lixin Jiang recently had the opportunity to discuss our gene therapy technology platform and expanding pipeline with Tamra Sami of BioWorld News. Read more here: https://bit.ly/4fnyiYB

NGGT has announced results from an investigator-initiated trial using its #genetherapy NGGT002 in the inherited metabolic disorder #phenylketonuria, which leads to a toxic buildup of the amino acid phenylalanine in the body. Administration of NGGT002 led to a level of plasma phenylalanine within the normal range after three weeks of drug administration for five out of six patients. Further, one patient demonstrated a plasma phenylalanine level within the normal range that persisted 40 weeks after the drug was administered. Dosages from this trial will be applied in our Phase I/II clinical trials, which are underway. Read the news release here: https://prn.to/3Ckh53s

Our website is now live! Go to https://nggtbio.com/ to find more about us, keep up to date on media coverage and news, and delve into our innovative #genetherapy technology, product pipeline and advanced manufacturing capabilities.

As a therapeutic product, gene therapies are regulated by the FDA. and must be tested for safety and efficacy in humans. Given the potential of #genetherapy to provide groundbreaking treatment options, the FDA is committed to prompt and thorough review to ensure that patients are able to access useful treatment options. Learn more here: https://bit.ly/3NH0auh

Our Chief Operating Officer and co-Founder Guang Qu joined Daniel Levine on the RARECast to discuss our proprietary technology platform and dual-functional vectors, our gene therapies for rare diseases, and our stringent development and manufacturing process. Please listen here: https://bit.ly/48oYorp

Our Chief Scientific Officer Guang Qu joined host Christopher Leidli of the Rx for Biotech podcast to discuss our technology platform and pipeline, and the promise that #genetherapy holds for multiple indications, from rare diseases to more common maladies. Tune in and listen to the episode here: https://apple.co/483TIHl

Bietti’s Crystalline Dystrophy (BCD) is a genetic disease caused by mutations in the CYP4V2 gene, which produces an enzyme involved in fatty acid metabolism. In BCD, crystalline deposits of fatty acids build up in sensitive eye regions, such as the cornea and retina, leading to deteriorating vision including trouble seeing in low light, or seeing certain colors. Often, these early symptoms progress to vision loss. Early diagnosis is hence important for timely treatment, which may include #genetherapy. Researchers continue to seek out new ways to diagnose BCD, and are applying tools such as machine learning in order to do so. Learn more about new diagnostic methods for BCD here: https://lnkd.in/emP2STwm

Recruiting for our phase I/II clinical trial to evaluate safety and efficacy of our #genetherapy asset NGGT-002 in classic #phenylketonuria (PKU) patients has begun! Learn more about the study and eligibility criteria here: https://bit.ly/3XITwIy